A large majorities of Americans favor a wide range of policy changes to curb prescription drug costs, including those that give government a greater role in negotiating or limiting drug prices, according to the latest Kaiser Family Foundation Health Tracking Poll.
A large majorities of Americans favor a wide range of policy changes to curb prescription drug costs, including those that give government a greater role in negotiating or limiting drug prices, according to the latest Kaiser Family Foundation (KFF) Health Tracking Poll.
The poll, which was conducted soon after revelations about a huge price increase for Mylan’s EpiPen epinephrine pen injector, revealed that 77% of respondents say prescription costs are unreasonable. There is widespread support for a variety of actions to keep costs down, including requiring drug companies to publicize information on how they set drug prices (86%), allowing the federal government to negotiate with drug companies to get a lower price on drugs for people on Medicare (82%), limiting the amount drug companies can charge for high-cost drugs for illnesses like cancer (78%), allowing Americans to buy prescription drugs imported from Canada (71%), and creating an independent group that oversees the pricing of prescription drugs (66%).
The poll found the respondents divided on the Affordable Care Act (ACA): 44% have a favorable view and 47% have an unfavorable view of the ACA. In deciding which candidate to vote for in the November 2016 presidential election, 44% of voters say the candidates’ personal characteristics, including their leadership ability, character, values, and experience, will make the biggest difference in how they vote for president than say the candidates’ stances on specific issues (39%) or the candidate’s political party (7%). Among registered voters, supports of Donald Trump say candidates’ stances on issues will affect who they vote for, whereas Hillary Clinton supporters say candidates’ personal characteristics (leadership ability, character, values, experience) make the biggest difference in who they vote for.
When asked about the role of healthcare issues in their choice of presidential candidate, two-thirds of voters say a candidate’s plan to address the future of the ACA is very important to their vote. Six in 10 say the same thing about a candidate’s plan to address the cost of health insurance premiums, 55% say the same about a candidate’s plan to address the cost of deductibles, and 51% say the same about a candidate’s plan to address prescription drug prices. However, more Clinton supporters than Trump supporters say a candidate’s plan to address a series of healthcare issues is “very important” to their vote.
Smaller segments of voters say a candidate’s plan to address the number of Americans who are uninsured (43%), the ongoing opioid epidemic (43%), or the Zika virus outbreak (26%) is very important to their vote. A majority (56%) say prescription drugs developed over the past 20 years have generally made the lives of people living in this country better, including 35% who say these drugs have made their lives “a lot better.” This is actually a decrease in the share of people who say this since March 2008, when 73% said that prescription drugs have made the lives of Americans better.
KFF noted that cost could be one reason why the share of Americans who say prescription drugs have made the lives of people in the US better is declining. The survey found a large majority (77%) of respondents now believe drug costs are unreasonable, and the share of Americans saying this has increased over the past year.
More Care Doesn't Equal Happier Patients in Traditional Medicare
March 17th 2025Data on care satisfaction, ease managing care, and out-of-pocket spending were the outcomes of interest for this new analysis that investigated the relationship between healthcare utilization and beneficiary experience within Traditional Medicare.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
March 14th 2025Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.
Read More